AR127054A1 - Composiciones y métodos para tratar sinucleinopatías - Google Patents

Composiciones y métodos para tratar sinucleinopatías

Info

Publication number
AR127054A1
AR127054A1 ARP220102483A ARP220102483A AR127054A1 AR 127054 A1 AR127054 A1 AR 127054A1 AR P220102483 A ARP220102483 A AR P220102483A AR P220102483 A ARP220102483 A AR P220102483A AR 127054 A1 AR127054 A1 AR 127054A1
Authority
AR
Argentina
Prior art keywords
seq
synuclein
acid sequence
amino acid
synucleinopathy
Prior art date
Application number
ARP220102483A
Other languages
English (en)
Spanish (es)
Inventor
Josefine Nielsen Sderberg
Pekka Kallunki
Louise Buur
Frank Larsen
Kumar Parshad Henrik Rajesh
Anne Sofie Markussen
Manning Mark Cornell
Derrick Spencer Katayama
Magdalena Gauden
John Smith
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of AR127054A1 publication Critical patent/AR127054A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ARP220102483A 2021-09-16 2022-09-13 Composiciones y métodos para tratar sinucleinopatías AR127054A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21197120 2021-09-16

Publications (1)

Publication Number Publication Date
AR127054A1 true AR127054A1 (es) 2023-12-13

Family

ID=78049153

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102483A AR127054A1 (es) 2021-09-16 2022-09-13 Composiciones y métodos para tratar sinucleinopatías

Country Status (12)

Country Link
US (6) US12077578B2 (cg-RX-API-DMAC7.html)
EP (1) EP4401770A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024534947A (cg-RX-API-DMAC7.html)
KR (1) KR20240055758A (cg-RX-API-DMAC7.html)
CN (1) CN117915952A (cg-RX-API-DMAC7.html)
AR (1) AR127054A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022348798A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230055A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024000753A1 (cg-RX-API-DMAC7.html)
IL (1) IL311344A (cg-RX-API-DMAC7.html)
MX (1) MX2024002970A (cg-RX-API-DMAC7.html)
WO (1) WO2023041524A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019114679A (ru) * 2016-11-15 2020-12-17 Х. Лундбекк А/С Средства, пути применения и способы лечения синуклеопатии
IL311344A (en) 2021-09-16 2024-05-01 H Lundbeck As Preparations and methods for the treatment of synoclinopathies
IL326387A (en) * 2023-09-14 2026-04-01 Hoffmann La Roche Antibody formulation
WO2025186235A1 (en) 2024-03-05 2025-09-12 H. Lundbeck A/S Compositions and methods for treating multiple system atrophy (msa)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2361928T3 (en) * 2003-05-19 2017-07-03 Prothena Biosciences Ltd Truncated fragments of alpha synuclein in Lewy body disease
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
WO2017176835A2 (en) * 2016-04-06 2017-10-12 Imago Pharmaceuticals, Inc. Therapeutic antibodies for treatment of neurodegeneration
RU2019114679A (ru) * 2016-11-15 2020-12-17 Х. Лундбекк А/С Средства, пути применения и способы лечения синуклеопатии
JOP20190227A1 (ar) * 2017-03-31 2019-09-30 Biogen Int Neuroscience Gmbh تركيبات وطرق لعلاج اعتلالات السينوكلين
IL311344A (en) 2021-09-16 2024-05-01 H Lundbeck As Preparations and methods for the treatment of synoclinopathies

Also Published As

Publication number Publication date
WO2023041524A3 (en) 2023-05-11
US12351624B2 (en) 2025-07-08
US12358975B2 (en) 2025-07-15
JP2024534947A (ja) 2024-09-26
US20240400661A1 (en) 2024-12-05
EP4401770A2 (en) 2024-07-24
CA3230055A1 (en) 2023-03-23
CL2024003713A1 (es) 2025-04-21
IL311344A (en) 2024-05-01
CN117915952A (zh) 2024-04-19
US20240400660A1 (en) 2024-12-05
AU2022348798A1 (en) 2024-03-14
US20240400662A1 (en) 2024-12-05
US12358974B2 (en) 2025-07-15
CL2024000753A1 (es) 2024-09-23
US20240025979A1 (en) 2024-01-25
US20250084156A1 (en) 2025-03-13
WO2023041524A2 (en) 2023-03-23
KR20240055758A (ko) 2024-04-29
US12077578B2 (en) 2024-09-03
MX2024002970A (es) 2024-03-27
US20260217807A1 (en) 2026-07-30

Similar Documents

Publication Publication Date Title
RU2359697C2 (ru) Введение средств для лечения воспаления
US10485844B2 (en) Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
AU2011325134B2 (en) Methods of treating rheumatoid arthritis using IL-17 antagonists
RU2759630C2 (ru) Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
KR101652530B1 (ko) 항 cd20 항체 또는 그 cd20-결합 항체 단편을 포함하는 만성 피로 증후군 및 근육통 뇌척수염 치료용 약학 조성물
TW202021614A (zh) 藉由投與pcsk9抑制劑抑制動脈粥狀硬化的方法
JP6554155B2 (ja) Il−17アンタゴニストを使用して汎発性膿疱性乾癬(gpp)を処置する方法
CL2024003713A1 (es) Anticuerpo monoclonal anti alfa-sinucleína; composición farmacéutica líquida; y su uso para tratar una sinucleinopatía.
US20180044428A1 (en) Compositions and methods for enhancing the efficacy of cancer therapy
EA031489B1 (ru) Способ лечения ревматоидного артрита
CN115427450A (zh) 通过施用il-4r拮抗剂治疗特应性皮炎的方法
CL2023000121A1 (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas
US20230183329A1 (en) Combination therapy for ttr amyloidosis
AR126614A1 (es) Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma
CO2025004617A2 (es) Composiciones y métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
JP2024532344A (ja) 自己免疫疾患の予防または治療のための抗体医薬品
DOP2025000008A (es) Composición farmacéutica de anticuerpo anti-cd20 y uso de la misma
US9486475B2 (en) PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
KR20260026080A (ko) 면역 매개 질환의 투여 및 치료와 면역 매개 질환과 관련된 바이오마커
AR130041A1 (es) Formulaciones de anticuerpos anti-tl1a
AR130865A1 (es) Agentes de unión de msln y cd3 y métodos de uso de estos
AR129198A1 (es) Nuevos anticuerpos anti-angptl3 adecuados para composiciones de concentración alta
AR123173A1 (es) Inmunoconjugados dirigidos a cd46 y métodos de uso de estos
EP2862877A1 (en) Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
JP2023504679A (ja) インターロイキン-17(il-17)アンタゴニストを使用して扁平苔癬を治療する方法